Updated from 1:41 p.m. EDT with new stock prices

Small-cap stocks, sharing the broader market's moodiness, couldn't find reason to rise Monday. The Russell 2000 lost 0.7% to 735.44, and the S&P SmallCap 600 fell 0.5% to 388.43.

Shares of Rimage ( RIMG), a Minneapolis maker of duplication systems for CDs, DVDs and laser discs, tumbled to new lows, falling 22.1% to $13.50. The company lowered is second-quarter earnings guidance to between 9 cents and 12 cents a share on revenue of $20 million to $22 million. Rimage had previously forecast EPS of 22 cents to 27 cents and revenue of $24 million to $26 million. Two analysts surveyed by Thomson Reuters are looking for 23 cents a share, and one analyst expects revenue of $24.9 million.

Shanghai-based fabless semiconductor company Spreadtrum Communications ( SPRD) gave up 16.2% to $7.84. Roth Capital downgraded the stock to hold from buy.

Taser ( TASR), which makes electronic control devices designed to zap criminals and others, also plunged to a new 52-week low, losing 11.3% to $6.12. The Scottsdale, Ariz.-based company saw rival Stinger Systems move for dismissal of a patent infringement case Taser had filed. In a separate case, a jury found extended application of a Taser device responsible for 15% of an arrest-related death. The jury awarded about $1 million in compensatory damages and $5.2 million in punitive damages against Taser.

On the winning side, Krispy Kreme Doughnut ( KKD), a branded retailer and wholesaler of doughnuts based in Winston-Salem, N.C., announced first-quarter earnings of $4 million, or 6 cents a share, vs. a loss of $7.4 million, or 12 cents a share, a year ago. Revenue declined 6.6% year over year to $103.6 million. Shares gained 12.9% to $3.86.

Cost Plus ( CPWM) shares climbed 9.2% to $3.33. The Oakland, Calif.-based furniture retailer announced Pier 1 Imports ( PIR) had proposed to buy Cost Plus for $4 a share in stock. Cost Plus is reviewing the unsolicited offer.

Finally, Nymox ( NYMX), a Hasbrouck Heights, N.J., pharmaceutical company, tacked on 28.4% to $3.98. The company announced it had started phase III development for NX-1207, an investigational product for the treatment of benign prostatic hyperplasia.

More from Investing

Jim Cramer on Intel CEO Brian Krzanich's Resignation: I Wish Him Well

Jim Cramer on Intel CEO Brian Krzanich's Resignation: I Wish Him Well

Jim Cramer: Disney Has Much More Staying Power Worldwide Than Netflix

Jim Cramer: Disney Has Much More Staying Power Worldwide Than Netflix

Former Employee Sued by Tesla Says He Saw Some 'Really Scary Things'

Former Employee Sued by Tesla Says He Saw Some 'Really Scary Things'

CoinShares: US Investors Should Think of Bitcoin as Digital Gold

CoinShares: US Investors Should Think of Bitcoin as Digital Gold

3 Killer Stocks Trading At Unfair Discounts

3 Killer Stocks Trading At Unfair Discounts